KORU Medical Systems, Inc. (KRMD)
| Previous Close | 2.2600 |
| Open | 2.2700 |
| Bid | 2.2300 x 400 |
| Ask | 2.3000 x 200 |
| Day's Range | 2.2400 - 2.3000 |
| 52 Week Range | 1.9780 - 4.2950 |
| Volume | |
| Avg. Volume | 104,119 |
| Market Cap | 103.427M |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
MAHWAH, N.J., May 01, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J., April 17, 2024--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financ
- Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J., April 11, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI).
